Researchi Therapeutics Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Researchi Therapeutics Co., Ltd. - overview
Established
2020
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Based in South Korea, and founded in 2000, Researchi Therapeutics Co. , Ltd. also known as Recerise, operates as a bio-venture company that specializes in developing treatment strategies for liver diseases. In June 2022, Recerise Therapeutics raised KRW 7 billion in series A funding from Timewise Investment, QUAD Ventures, Partners Investment, Creation Investment Advisory, and CKD Venture Capital.
As of June 2023, the company is led by its CEO, Yongbae Kim. Recerise Therapeutics Co. , Ltd. is developing a liquid biopsy-based companion diagnosis technology for the treatment of liver disease that aligns with the liver's natural functions.
The company focuses on the liver's role in immune response and metabolism and provides solutions that address the underlying causes of liver diseases.
Current Investors
CKD Venture Capital, Partners Investment, CJ Investment
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.recerise.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.